CyPep-1 Peptide Composition for Treating Neoplastic Lesions
Summary
USPTO granted patent US12599646B2 to CYTOVATION ASA covering a pharmaceutical composition comprising therapeutic peptide CyPep-1 for treating neoplastic lesions, particularly warts. The patent, with 16 claims, was filed on March 10, 2020, and includes CPC classifications related to peptide formulations and therapeutic applications.
What changed
USPTO issued patent US12599646B2 to CYTOVATION ASA for a therapeutic peptide composition (CyPep-1) intended for treating neoplastic lesions and warts. The patent grants exclusive rights to the pharmaceutical composition and its therapeutic use.
For patent holders, investors, and pharmaceutical companies, this grant represents an enforceable IP asset that may affect freedom-to-operate analyses for competing wart or lesion treatments. The patent's broad neoplastic indication scope could impact development strategies for similar topical or injectable peptide therapeutics. This is a routine patent grant with no immediate compliance obligations.
What to do next
- Monitor for potential licensing opportunities
- Review freedom-to-operate considerations if developing similar peptide therapeutics
- Contact CYTOVATION ASA for licensing inquiries
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Peptide-containing composition for use for treating neoplastic lesions
Grant US12599646B2 Kind: B2 Apr 14, 2026
Assignee
CYTOVATION ASA
Inventors
Charles Evans, Cameron Stevenson, Suzanne Edmunds
Abstract
The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.
CPC Classifications
A61K 38/03 A61K 47/10 A61K 47/14 A61K 47/24 A61K 47/44 A61K 9/0014 A61K 9/06 A61K 9/08 A61K 9/10 A61P 17/12
Filing Date
2020-03-10
Application No.
17791270
Claims
16
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.